← Leaderboards
Young Mee Lee
Tufts Medical Center
$93,073
Attributed
$93,073
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$93,073 · 3
By mechanism
M01$93,073 · 3
Top collaborators
No co-investigators on record.
Most similar at Tufts Medical Center
Same institution · by research overlap
- Paul M Hassoun$13,983,399
- Francine M Foss$122,062
- David J Greenblatt$6,267,969
- Ronenn Roubenoff$1,390,468
- Geraldine A Finlay$1,722,600
Others in their field
Top investigators on “Ursodeoxycholate”
- James Lorenzen Boyer · Yale University$8,666,192
- Keith D. Lindor · Mayo Clinic Coll Of Medicine, Rochester$5,900,833
- Burton Combes · University Of Texas Sw Med Ctr/Dallas$4,586,644
- Kris Kowdley · University Of Washington$4,090,213
- Danxia Yu · Vanderbilt University Medical Center$3,769,603
- Jeffrey W Smith · Burnham Institute For Medical Research$2,794,906
Research focus
UrsodeoxycholateClinical ResearchCombination ChemotherapyHuman SubjectHuman Therapy EvaluationMethotrexateAntibioticsLiver Disorder ChemotherapySclerosisBiliary Tract DisorderClinical TrialsPrimary Sclerosing CholangitisPatient Oriented ResearchBiliary Tract Disorder ChemotherapyLongitudinal Human Study
Grant awards (6)
MICRONUTRIENTS AND COGNITIVE IMPAIRMENT IN THE HOMEBOUND ELDERLY$41,576
M01 · FY2005 · RR
SCHLEROSING CHOLANGITIS: A PROSPECTIVE PILOT TRIAL OF DIFFERENT TREATMENTS$967
M01 · FY2005 · RR
Schlerosing Cholangitis: A Prospective Pilot Trial of Different Treatments$7,791
M01 · FY2004 · RR
TRIAL OF 4 TREATMENT REGIMENS IN PTS WITH PRIMARY SCLEROSING CHOLANGITIS$0
M01 · FY2002 · RR
TRIAL OF 4 TREATMENT REGIMENS IN PTS WITH PRIMARY SCLEROSING CHOLANGITIS$0
M01 · FY2001 · RR
TRIAL OF 4 TREATMENT REGIMENS IN PTS WITH PRIMARY SCLEROSING CHOLANGITIS$42,739
M01 · FY2000 · RR